Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation
(Published 11 June 2013)
Cite this as: BMJ 2013;346:f3782
- Zosia Kmietowicz
Drug regulators and manufacturers have been criticised for failing to take enough action in response to research highlighting the potential serious adverse effects of new forms of drugs used to treat type 2 diabetes, known as glucagon-like peptide-1 (GLP-1) based drugs.
A joint investigation by the BMJ and Channel 4’s Dispatches current affairs programme has found that concerns about the drugs, also called incretin therapies, started to emerge in 2007.1 Since then many published reports, regulatory documents, and adverse event databases have highlighted concerns about the safety of these drugs and linked them with an increased risk of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial